Lonza Group, biotechnology

Lonza Group stock reports 16 percent H1 growth

Published on 09/24/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza Group stock stood at CHF 563.00 on September 24, 2026, after reaching CHF 566.60 intraday. Core EBITDA margin reached 34.8 percent in H1 2026.

Schwarz-Weiß-Reportage: Wissenschaftler im Schutzanzug am Mikroskop, dokumentarischer Stil
Lonza CH0013841017 Forscher im Schutzanzug am Mikroskop dokumentarisch in Schwarz Weiss fotografiert, Illustration mit AI erstellt.

Lonza Group stock was trading at CHF 563.00 on SIX on September 24, 2026, after reaching an intraday high of CHF 566.60. The contract development and manufacturing organization reported 16 percent H1 2026 sales growth at constant exchange rates, keeping operational execution at the center of the investment case.

H1 growth raises the bar

Lonza lists its Half-Year Results 2026 among the latest investor materials, with the release dated July 22, 2026. The company said H1 sales rose 16 percent at constant exchange rates, while core EBITDA margin reached 34.8 percent.

The comparison with the prior period is important because growth is not coming with a flat profitability profile. For investors, the combination of double-digit sales expansion and a 34.8 percent core EBITDA margin gives the H1 report more weight than a revenue figure alone.

Advanced Synthesis grows 28 percent

At the Morgan Stanley healthcare conference on September 16, 2026, management described Advanced Synthesis as a key contributor, with H1 growth of 28 percent. Investing.com also reported that the segment margin reached 48 percent, a level management expects to normalize over time.

The same conference highlighted a second numerical checkpoint. Lonza expects capital expenditure to normalize to 14 percent to 19 percent of sales, compared with a level above 20 percent during the current investment phase, which could improve cash conversion as new capacity comes online.

Stock trades near the daily high

Lonza shares opened at CHF 559.20 on September 24, 2026 and reached CHF 563.00 by the midday market update, an increase of 0.68 percent from the opening level. The intraday high of CHF 566.60 stood CHF 3.60 above the quoted price.

The price move was measured rather than sharp, with the stock up 0.2 percent in the SIX SX session at the cited update. That trading pattern places the market response below the pace of H1 sales growth, leaving margin durability and capital spending discipline as the more useful operating markers.

Trading level remains measurable

Lonza Group stock was trading at CHF 563.00 on SIX on September 24, 2026. The quoted price was intraday, while the session high was CHF 566.60 and the opening level was CHF 559.20.

Lonza Group stock facts

  • Company: Lonza Group AG
  • Ticker: LONN
  • Trading venue: SIX Swiss Exchange
  • Price as of September 24, 2026: CHF 563.00, intraday
  • Sector / Industry: Health Care / Biotechnology and Medical Research
  • Index membership: SMI

Disclaimer...

en | boerse | 70177286 |